Hoppa till innehål
board-image-christopher-nowak

Chris Nowak

Chief Medical Officer

I am passionate about building teams and developing treatments that address unmet medical needs in immunology, inflammation, respiratory diseases and cancer, and that can make a meaningful difference for affected individuals, their families and society.

Find me somewhere between Stockholm/Uppsala, Mumbai, and Hyderabad.

MD (Oxford), PhD (Uppsala) and Psychologist (MSc, BSc), with 14+ years of experience in the biopharma industry, academic research, clinical work, regulatory interactions, life sciences investing, biostatistics, entrepreneurship and company building. Includes working with investors, fundraising, and C-suite roles in public and private biotech companies, and more than 60 peer-reviewed publications (>20 as first or senior author).

Christophers Timeline

  • Chief Medical Officer, Buzzard Pharmaceuticals

  • Leading the clinical and medical development of Isunakinra, a high-potency IL-1 inhibitor for solid tumors, in combination with PD-1 checkpoint inhibition. The program is currently in Phase 2a clinical development in the US.

 

  • Chief Medical Officer, Melius Pharma

  • Leading an international Phase 2 clinical program for ME-015 in chronic cough associated with idiopathic pulmonary fibrosis. Responsible for clinical, regulatory and business development strategy in a private, investor-backed biotech company.

 

  • Chief Medical & Business Officer, Diamyd Medical

  • Former CMO and CBO of a public biotech company, leading a registrational Phase 3 program in autoimmune Type 1 Diabetes and LADA. Played a key role in regulatory strategy, FDA interactions, and successful capital raises in challenging market conditions.

 
 

  • Clinical Lead, Egle Therapeutics

  • Led first-in-human clinical entry and early clinical strategy for EGL-003, a novel Treg agonist targeting autoimmune diseases, within a Paris-based clinical-stage biotech.

 

  • Chief Executive Officer, Aeriant Therapeutics

  • CEO of a first-in-class inhaled therapy program targeting small-airway dysfunction in COPD, progressing toward first-in-human clinical testing.

 

  • Founder & CEO, Ojas Therapeutics

  • Founder and CEO of a Swedish-Indian clinical-stage immunotherapy biotech focused on innovative immune-modulating therapies.

 

  • Board Member, OncoZenge

  • Board member of a public, late-stage biotech company developing a novel treatment for oral pain in cancer patients, supporting the company through Phase 3 readiness, partnerships and market entry preparation.

 

Bli kontaktad

Fyll i formuläret så kontaktar vi dig så snart vi kan.

Obligatoriskt

Cookiesamtycke

På webbplatsen används nödvändiga kakor för att webbplatsen ska fungera på ett bra sätt. Du kan även välja att samtycka till kakor för statistikinsamling.